admin
America built the world’s greatest health system through private-sector grit and doctor-driven care, not bureaucratic mandates. At the recent Forbes Iconoclast Summit, Shalabh Gupta — founder and CEO of Unicycive Therapeutics — laid out a familiar promise: AI can remove friction in drug development and patient care, speed clinical trials, and help get therapies to people faster. His appearance underscored that conservative pragmatism — embrace tools that deliver results to patients while defending the primacy of clinicians.
Gupta told Forbes interviewers that AI is being put to practical use across biotech operations, from competitive intelligence to mapping patient populations, and that these tools are meant to augment clinicians rather than replace them. That’s the right approach: use technology to make doctors more effective and efficient, not to centralize decisions inside Silicon Valley algorithms. Americans should cheer innovations that cut red tape and reduce costs without surrendering medical judgment to opaque models.
Unicycive itself is a small, doctor-founded biotech focused on real unmet needs, and Gupta’s resume shows a mix of bedside experience and business acumen that conservatives respect — physician, entrepreneur, and executive who built a company from the ground up. Companies like this, led by people who have actually treated patients, deserve a seat at the table when policymakers debate AI regulation and funding priorities. When innovation comes from clinicians who answer to patients rather than to grant committees, the results are more likely to serve hardworking families.
The promise Gupta described — faster trials, smarter patient recruitment, and streamlined development pathways — is exactly the sort of market-driven efficiency conservatives should back. If AI helps shrink trial timelines and bring down the cost of developing a drug, more therapies reach patients sooner and taxpayers and insurers save money. But efficiency must not become an excuse for overlooking safety, transparency, or the doctor-patient relationship that conservatives rightly defend.
Still, we must not be naive about the risks. Big tech firms and activist bureaucrats will see AI’s promise as an opportunity to centralize control, harvest patient data, and impose one-size-fits-all mandates. Conservatives should insist on clear guardrails: patient consent, data ownership protections, and policies that preserve physician authority and clinical judgment. Innovation without freedom is not progress — and freedom without responsibility is chaos.
Unicycive’s focus on kidney disease shows the type of targeted innovation that deserves support; the company has prioritized therapies that address unmet needs in an underserved area of medicine. Small biotechs pursuing specialized treatments are the engines of medical progress, and when they pair clinician leadership with smart use of AI, the payoff can be measured in lives saved and families kept whole. That train must be encouraged, not derailed by overreach.
Patriotic conservatives should therefore embrace a simple bargain: welcome AI that empowers doctors, rewards entrepreneurial risk, and delivers measurable benefits to patients, while demanding accountability, patient privacy, and medical transparency. Congress and state capitals should pass pro-innovation, pro-patient rules that keep regulators honest and give American companies the lead in life-saving technologies. The working men and women who pay for healthcare deserve nothing less than a system that uses every legitimate tool to heal them — provided those tools preserve human dignity and clinical sovereignty.
